What are the different brands of adalimumab available on the market?

Adalimumab (Adalimumab) is one of the most widely used biopharmaceuticals in the world, with many different brands available on the market. The original drug of adalimumab is launched by AbbVie Pharmaceuticals (AbbVie) under the trade name Humira. It is the most well-known brand and the first approved version. Since being approved by the FDA in 2002, Humira has become one of the best-selling immunotherapy drugs in the world.

In addition to the original drugHumira, generic drugs of adalimumab are also on the market in many countries and regions. As the patent of the original drug expires, more and more pharmaceutical companies have begun to produce generic versions of adalimumab, which are often called "biosimilars." Biosimilar drugs are drugs that are highly similar to the original drugs after rigorous testing and are consistent in safety, effectiveness and pharmacological properties.

Common adalimumab biosimilars on the market include:

Amjevita: Produced by Amgen, it is the first biosimilar to adalimumab and has been approved in both the United States and Europe.

Cyltezo: Produced by Boehringer Ingelheim of Germany, it is another biosimilar of adalimumab.

Hulio: Produced by Samsung Bioepis, it is a biosimilar drug made in South Korea.

Idacio: Produced by Novartis and sold globally, it is a biosimilar of adalimumab.

These biosimilars are gradually replacing originator drugs in many regions and often have lower prices, allowing patients to obtain treatment in a more economical way. Although they are generic drugs, the quality and efficacy of these products have been rigorously scrutinized and are therefore very close to Humira in terms of therapeutic effect.

Reference materials:https://www.drugs.com/adalimumab.html